TY - JOUR
T1 - Microglia depletion reduces neurodegeneration and remodels extracellular matrix in a mouse Parkinson’s disease model triggered by α-synuclein overexpression
AU - Zhang, Zhen
AU - Niu, Kun
AU - Huang, Taoying
AU - Guo, Jiali
AU - Xarbat, Gongbikai
AU - Gong, Xiaoli
AU - Gao, Yunke
AU - Liu, Feiyang
AU - Cheng, Shan
AU - Su, Wenting
AU - Yang, Fei
AU - Liu, Zhaoyuan
AU - Ginhoux, Florent
AU - Zhang, Ting
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12/1
Y1 - 2025/12/1
N2 - Chronic neuroinflammation with sustained microglial activation occurs in Parkinson’s disease (PD), yet the mechanisms and exact contribution of these cells to the neurodegeneration remains poorly understood. In this study, we induced progressive dopaminergic neuron loss in mice via rAAV-hSYN injection to cause the neuronal expression of α-synuclein, which produced neuroinflammation and behavioral alterations. We administered PLX5622, a colony-stimulating factor 1 receptor inhibitor, for 3 weeks prior to rAAV-hSYN injection, maintaining it for 8 weeks to eliminate microglia. This chronic treatment paradigm prevented the development of motor deficits and concomitantly preserved dopaminergic neuron cell and weakened α-synuclein phosphorylation. Gene expression profiles related to extracellular matrix (ECM) remodeling were increased after microglia depletion in PD mice, which were further validated on protein level. We demonstrated that microglia exert adverse effects during α-synuclein-overexpression-induced neuronal lesion formation, and their depletion remodels ECM and aids recovery following insult.
AB - Chronic neuroinflammation with sustained microglial activation occurs in Parkinson’s disease (PD), yet the mechanisms and exact contribution of these cells to the neurodegeneration remains poorly understood. In this study, we induced progressive dopaminergic neuron loss in mice via rAAV-hSYN injection to cause the neuronal expression of α-synuclein, which produced neuroinflammation and behavioral alterations. We administered PLX5622, a colony-stimulating factor 1 receptor inhibitor, for 3 weeks prior to rAAV-hSYN injection, maintaining it for 8 weeks to eliminate microglia. This chronic treatment paradigm prevented the development of motor deficits and concomitantly preserved dopaminergic neuron cell and weakened α-synuclein phosphorylation. Gene expression profiles related to extracellular matrix (ECM) remodeling were increased after microglia depletion in PD mice, which were further validated on protein level. We demonstrated that microglia exert adverse effects during α-synuclein-overexpression-induced neuronal lesion formation, and their depletion remodels ECM and aids recovery following insult.
UR - http://www.scopus.com/inward/record.url?scp=85217783096&partnerID=8YFLogxK
U2 - 10.1038/s41531-024-00846-4
DO - 10.1038/s41531-024-00846-4
M3 - Article
AN - SCOPUS:85217783096
SN - 2373-8057
VL - 11
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
IS - 1
M1 - 15
ER -